FDA Approves Opdivo for Advanced Renal Cell Carcinoma
The FDA has approved Opdivo for the treatment of advanced renal cell carcinoma, marking a significant advancement in cancer therapy options for patients.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 09, 2026
The U.S. Food and Drug Administration (FDA) has granted approval for nivolumab (Opdivo), manufactured by Bristol Myers Squibb, for the treatment of advanced renal cell carcinoma (RCC). This FDA Opdivo approval includes its use as a first-line treatment in combination with ipilimumab (Yervoy) for patients with intermediate- and poor-risk advanced RCC. This decision marks a significant advancement in immunotherapy options for RCC, offering a shift from traditional VEGF-targeted therapies.
Drug Overview
Nivolumab (Opdivo) is a fully human monoclonal antibody that functions as a PD-1 immune checkpoint inhibitor. It is approved for the treatment of advanced renal cell carcinoma (RCC). The drug works by blocking the interaction between programmed death-1 (PD-1) and its ligands, PD-L1 and PD-L2, thereby enhancing T-cell-mediated immune responses against tumor cells.
Clinical Insights
The approval of nivolumab for advanced RCC is supported by data from two key Phase III clinical trials: CheckMate 025 and CheckMate 214.
CheckMate 025 demonstrated a significant overall survival (OS) benefit of nivolumab compared to everolimus in previously treated patients with advanced RCC. CheckMate 214 supported the first-line combination therapy of nivolumab plus ipilimumab, showing superior efficacy in treatment-naïve patients with intermediate- and poor-risk advanced RCC. The primary endpoint for both trials was overall survival (OS).
The safety profile of nivolumab is characterized by immune-related adverse events, including pneumonitis, colitis, hepatitis, endocrinopathies such as hypothyroidism, and skin reactions. Common non-immune adverse events include fatigue, rash, and infusion-related reactions. Combination therapy with ipilimumab increases the frequency and severity of immune-mediated toxicities.
Regulatory Context
The nivolumab approval was based on data from Phase III clinical trials. Post-marketing commitments and pharmacovigilance are standard for this approval.
Safety signals include immune-related adverse events such as pneumonitis, colitis, hepatitis, endocrinopathies, and skin reactions, as well as common non-immune adverse events like fatigue and rash. Combination therapy with ipilimumab increases the frequency and severity of immune-mediated toxicities.
Market Impact
Nivolumab, especially in combination with ipilimumab, competes with VEGF tyrosine kinase inhibitors like sunitinib and pazopanib, as well as mTOR inhibitors such as everolimus, in the advanced RCC treatment landscape. The U.S. market for advanced RCC treatments addresses a significant unmet need for durable and tolerable therapies, with several thousand patients diagnosed annually.
This approval strengthens Bristol Myers Squibb's position in oncology and RCC treatment and is anticipated to impact treatment guidelines and prescribing patterns.
Future Outlook
Future developments may include label expansions for nivolumab in combination with other agents, as well as ongoing trials to assess its efficacy in different RCC patient populations. Further studies may explore its potential in earlier stages of the disease.
Frequently Asked Questions
What is nivolumab (Opdivo)?
Nivolumab (Opdivo) is a fully human monoclonal antibody designed to block the PD-1 receptor, enhancing the body's immune response against cancer cells.
What are the common side effects of nivolumab?
Common side effects include immune-related adverse events such as pneumonitis, colitis, hepatitis, endocrinopathies, and skin reactions, as well as fatigue and rash.
What is the role of nivolumab in treating advanced renal cell carcinoma?
Nivolumab is used to treat advanced renal cell carcinoma (RCC), particularly in patients who have been previously treated or as a first-line treatment in combination with ipilimumab for intermediate- and poor-risk patients.
References
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-09.
Senior Medical Editor
Dr. Sarah Chen is a board-certified internist and former FDA clinical reviewer with 15+ years of experience in pharmaceutical regulatory affairs. She received her MD from Johns Hopkins and her PhD in ...
